Printer Friendly

NuVasive names new independent directors.

M2 PHARMA-February 12, 2016-NuVasive names new independent directors

(C)2016 M2 COMMUNICATIONS

NuVasive Inc (NASDAQ: NUVA), a medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, has named Robert F Friel and Donald J Rosenberg as its independent directors, effective 12 February 2016, it was reported yesterday.

Friel will serve as a member of the board's Compensation Committee and Rosenberg will serve as a member of the board's Compensation Committee and the Nominating and Corporate Governance Committee.

Friel has more than 35 years of finance and operational experience and presently serves as chairman, chief executive officer and president of PerkinElmer Inc.

Rosenberg possesses extensive expertise in the areas of corporate governance, compliance, law department management, litigation, securities regulation, intellectual property and competition issues, which he developed over a 40-year career at Fortune 500 technology companies. He currently serves as executive vice president, general counsel and corporate secretary of Qualcomm Incorporated.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 12, 2016
Words:165
Previous Article:Bayer chooses Oracle's health sciences offerings.
Next Article:RTI Surgical enters into spinal implant license agreement with Oxford Performance Materials.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters